Physician
Oncology
Dr. Ronald L. Drengler, MD
|
|
Give Review
Ronald L. Drengler is an expert in the field of Oncology. He received awards:"Super Doctor" and "Top MD". Ronald L. Drengler is a published physician as well. He has 21 publications published. The latest was: Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR... Ronald L. Drengler is registered with Medicare and accepts Medicare payments.
Publications
- Weekly combination chemotherapy with docetaxel and gemcitabine as first-line treatment for elderly patients and patients with poor performance status who have extensiv...
- A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms.
- Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced s...
- Pharmacokinetics and bioequivalence of a combined Oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients wit...
- Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced Cancer.
- Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant Systemic exposure to paclitaxel.
- DX-8951f, a hexacyclic camptothecin Analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
- Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies.
- A phase I and pharmacological study of proTracted infusions of crisnatol mesylate in patients with solid malignancies.
- Phase I and pharmacokinetic study of the Oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies.
- Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid Tumors.
- Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid Tumors.
- A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid Tumors.
- Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR...
- Alternative dosing schedules for irinotecan.
- A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral Brain edema.
- Docetaxel in combination with fluorouracil: study design and preliminary results.
- New antiCancer agents in clinical development.
- Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies.
- Genotypic and allelic frequencies of SULT1A1 polymorphisms in women receiving adjuvant tamoxifen therapy.
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Super Doctor
- Top MD
Education
-
University of Texas Health Science Center -
Universidad Nacional de Asuncion Faculty of Medicine
Drug Facts
| NPI NUMBER | 1265459168 | |
| NPPES Provider LastName | DRENGLER | |
| NPPES Provider FirstName | RONALD | |
| NPPES Provider ZIPCode | 782293307 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 635.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 63.0 | |
| Percent Opioid Claims | 9.92 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1265459168 |
| Last Name Of The Provider | DRENGLER |
| First Name Of The Provider | RONALD |
| View All |
Similar Doctors
|
|
Dr. Noboru Oishi, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas D. Fisher, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ting-Wei Lu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sukeshi R. Patel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anthony W. Tolcher, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vijay K. Gunuganti, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jesse E. Medellin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amita Patnaik, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Alain C. Mita, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. John Sarantopoulos, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|